S1 Ep218: Unraveling Key Hematologic Oncology Developments at ASCO 2026

About this episode

The episode discusses key hematologic oncology developments presented at the 2026 ASCO Annual Meeting.

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations. Braunstein is an associate professor in the Department of Medicine and course co-director of the Hematology/Oncology System at NYU Grossman Long Island School of Medicine, as well as the fellowship program director of Hematology/Oncology at NYU Langone Health. Zahid is a first-year fellow at NYU Grossman Long Island School of Medicine. The discussion focused on the following abstracts: · Abstract 7512 o Combining belantamab mafodotin-blmf (Blenrep) with daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone produced rapid activity among patients with transplant-ineligible newly diagnosed multiple myeloma in the phase 1/2 BelaDRd study (EUCT-2024-515634-32). o The progression-free survival…

People in this episode

Host: CancerNetwork

Guests: Marc J. Braunstein, MD, PhD, Sofia Zahid, MD

Topics covered

• hematologic oncology
• ASCO 2026
• multiple myeloma
• leukemia
• lymphoma
• clinical practice

Keywords

• hematologic oncology
• ASCO 2026
• multiple myeloma
• leukemia
• lymphoma
• clinical practice
• Revumenib
• belantamab mafodotin-blmf

Mentioned in this episode

Organizations: American Society for Transplantation and Cellular Therapy, NYU Grossman Long Island School of Medicine, NYU Langone Health

Products: belantamab mafodotin-blmf, daratumumab, lenalidomide, dexamethasone, Revumenib

More episodes of Oncology On The Go

• S1 Ep217: Integrating Exercise and Lifestyle Intervention Into Oncologic Therapy · June 1, 2026 · 29 min
• S1 Ep216: How the Landscape of GI Oncology is Evolving | A 2026 ASCO Preview · May 28, 2026 · 29 min
• S1 Ep215: Navigating The Dynamic Landscape of Stem Cell Transplantation · May 25, 2026 · 11 min
• S1 Ep214: Are Zedoresertib and Lunresertib an Efficacious Combo Across Solid Tumors? · May 18, 2026 · 13 min
• S1 Ep213: What Does the Future Hold for Immune Effector Cell Therapies? · May 11, 2026 · 12 min
• S1 Ep212: Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer · May 4, 2026 · 20 min